Comparing Presbia (OTCMKTS:LENSF) & Perspective Therapeutics (NYSE:CATX)

Perspective Therapeutics (NYSE:CATX) and Presbia (OTCMKTS:LENSF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation and analyst recommendations.

Valuation & Earnings

This table compares Perspective Therapeutics and Presbia”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	N/A	N/A	-$46.51 million	N/A	N/A
Presbia	N/A	N/A	N/A	N/A	N/A

Risk and Volatility

Perspective Therapeutics has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, Presbia has a beta of 5.91, suggesting that its stock price is 491% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Perspective Therapeutics and Presbia, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	7	3	3.18
Presbia	0	0	0	0	0.00

Perspective Therapeutics currently has a consensus price target of $12.56, indicating a potential upside of 223.60%. Given Perspective Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Perspective Therapeutics is more favorable than Presbia.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are held by institutional investors. 3.7% of Perspective Therapeutics shares are held by insiders. Comparatively, 74.2% of Presbia shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Perspective Therapeutics and Presbia’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Presbia	N/A	N/A	N/A

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.